Literature DB >> 1527410

Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain.

S P Fisher-Hoch1, T L Brammer, S G Trappier, L C Hutwagner, B B Farrar, S L Ruo, B G Brown, L M Hermann, G I Perez-Oronoz, C S Goldsmith.   

Abstract

African filoviruses have caused outbreaks of fulminating hemorrhagic fever among humans. In 1989, related filoviruses were isolated from cynomolgus monkeys imported into the United States from the Philippines. The pathogenic potential of these new filoviruses was compared in 16 Asian monkeys (Macaca fascicularis-cynomolgus) and 16 African monkeys (Cercopithecus aethiops-African green) using African filoviruses from Zaire (Ebola virus) and Sudan or Asian filoviruses (Reston and Pennsylvania). African filovirus infections resulted in earlier death (P = .005), had a shorter duration of disease and median incubation period (3-4 vs. 7 days), and had earlier peak viremia (5-7 vs. 7-9 days). African green monkeys showed significantly higher survival than cynomolgus monkeys (P less than .01), and some were asymptomatic as have been humans accidentally infected with Asian filovirus. Rechallenge experiments showed that protection in survivors of filovirus infections against fatal challenge with Ebola (Zaire) virus is unpredictable. The minimal clinical disease observed in humans infected with the Reston strain is consistent with host- and virus-dependent pathogenicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1527410     DOI: 10.1093/infdis/166.4.753

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

Review 1.  Filovirus vaccines.

Authors:  Steven B Bradfute; John M Dye; Sina Bavari
Journal:  Hum Vaccin       Date:  2011-06-01

2.  Antigen capture enzyme-linked immunosorbent assay for specific detection of Reston Ebola virus nucleoprotein.

Authors:  Tetsuro Ikegami; Masahiro Niikura; Masayuki Saijo; Mary E Miranda; Alan B Calaor; Marvin Hernandez; Luz P Acosta; Daria L Manalo; Ichiro Kurane; Yasuhiro Yoshikawa; Shigeru Morikawa
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

3.  Assessment of rodents as animal models for Reston ebolavirus.

Authors:  Emmie de Wit; Vincent J Munster; Samia A Metwally; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

4.  Computer simulations of proteolysis of Marburg and Ebola-Zaire filovirus coded proteins to generate nonapeptides with motifs of known HLA class I haplotypes and detection of antigenic domains in the viral glycoproteins.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

5.  Ebola: history, treatment, and lessons from a new emerging pathogen.

Authors:  Kevin S Harrod
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-12-12       Impact factor: 5.464

Review 6.  Animal Models of Ebolavirus Infection.

Authors:  Marisa C St Claire; Dan R Ragland; Laura Bollinger; Peter B Jahrling
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

7.  Early immune responses accompanying human asymptomatic Ebola infections.

Authors:  E M Leroy; S Baize; P Debre; J Lansoud-Soukate; E Mavoungou
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

8.  Isolation and phylogenetic characterization of Ebola viruses causing different outbreaks in Gabon.

Authors:  M C Georges-Courbot; A Sanchez; C Y Lu; S Baize; E Leroy; J Lansout-Soukate; C Tévi-Bénissan; A J Georges; S G Trappier; S R Zaki; R Swanepoel; P A Leman; P E Rollin; C J Peters; S T Nichol; T G Ksiazek
Journal:  Emerg Infect Dis       Date:  1997 Jan-Mar       Impact factor: 6.883

9.  Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis.

Authors:  Nadia Wauquier; Pierre Becquart; Cindy Padilla; Sylvain Baize; Eric M Leroy
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

Review 10.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.